Quantcast

Saudi Arabia Pharmaceutical Market Sales at US$7B by 2018 Forecasts a New Research Available at MarketReportsOnline.com

September 15, 2013

Saudi Arabia Pharmaceutical Market Opportunity Analysis is the new industry research report now available with MarketReportsOnline.com.

Dallas, Texas (PRWEB) September 15, 2013

Pharmaceuticals products sales in Saudi Arabia are expected to surpass US$ 7 Billion by 2018 as compare to US$ 4 Billion 2012. Saudi Arabia is expected to emerge as one of the fastest growing markets in future. The country is one of the most developed and technologically advanced medical sectors in the GCC Region with modern equipment and amenities. Saudi Arabia Pharmaceutical Market Opportunity Analysis (http://www.marketreportsonline.com/270352.html) report gives comprehensive insights on following aspects related to pharmaceutical market: Market Overview, Drug Pricing system, Disease Prevalence, Market by segment: Generics, Branded & OTC, Favorable Market dynamics and Regulatory Framework.

Saudi Arabia Pharmaceutical market has recorded significant growth over the years owing to various factors like increasing ageing population mostly in the above 60 years bracket, changing demographics and rise in the incidence of lifestyle diseases, increased spending power, result driven government initiatives to promote the growth of indigenous pharmaceutical companies. Inspite of all the progress, the pharmaceutical market in the Saudi Arabia is still in an emerging phase, and the drug manufacturing is at a relatively nascent stage owing to many challenges, which need to be resolved.

Saudi Arabia relies substantially on imports of pharmaceutical products, primarily from Europe, to meet local demand as a result of insufficient domestic drug production and lack of indigenous research capabilities. Government is taking efforts to promote FDI in the pharmaceutical sector especially directed to help development of skills of local companies to manufacture patented medicines as well. Policies like free trade agreements have played a significant role in encouraging foreign investments. Increased penetration of the healthcare sector by insurance providers, price regulation guidelines to ensure uniformity in pricing and dedicated healthcare reforms, have further ensured growth of pharmaceutical market in recent years.

Table of Contents for the report Saudi Arabia Pharmaceutical Market Opportunity Analysis (http://www.marketreportsonline.com/270352-toc.html) include:

1. Saudi Arabia Pharmaceutical Market Overview

1.1 Current Market Overview

1.2 Drug Pricing System

1.3 Disease Prevalence

2. Pharmaceutical Market by Segment

2.1 Branded Drugs

2.2 Generic drugs

2.3 OTC

3. Favourable Market Dynamics

3.1 Largest Market in Middle East

3.2 Promotion of Domestic Pharmaceutical Industry

3.3 Well Established Regulatory Framework

3.4 Demand for OTC & Generics Drugs

3.5 Import Dependent Market

3.6 Challenges to be Resolved

3.7 Future Growth Avenues

4. Regulatory & Policy Framework

4.1 Drug Approval Process (Generics, Biologicals, Radipharmaceuticals &New Chemical Entity)

4.2 Monoclonal Antibodies and Related Products Quality Guideline

4.3 Law of Pharmaceutical Establishments and Preparations

4.4 Guidelines on Biosimilars

4.4.1 Insulin

4.4.2 Interferons

4.4.3 Erythropoietin

4.4.4 Granulocyte-Colony Stimulating Factor

4.4.5 Human Growth Hormone

5. Competitive Landscape

5.1 SPIMACO

5.2 Tabuk Pharmaceuticals

5.3 Jamjoom Pharma

5.4 Julphar (Gulf Pharmaceutical Industries)

5.5 GSK

5.6 Pfizer

5.7 Novartis

5.8 Astra

List of Tables

Table 1-1: Pricing History and Legal Background in Saudi Arabia

Table 1-2: Drug Pricing for Generics

Table 1-3: Drug Pricing for Fixed Combinations

List of Figures

Figure 1-1: Saudi Arabia Pharmaceutical Market (US$ Billion), 2012-2018

Figure 1-2: Saudi Arabia Pharmaceutical Market by Segment (US$ Billion), 2012-2018

Figure 1-3: Saudi Arabia Pharmaceutical Market by Segment (%), 2012 & 2018

Figure 1-4: Factors Driving Growth in Saudi Pharmaceuticals Market

Figure 1-5: Components of Drug Pricing System in Saudi Arabia

Figure 1-6: Burden of Communicable & Non Communicable Diseases in Saudi Arabia, 2012 & 2030

Figure 1-7: Leading Causes of Death in Saudi Arabia, 2011

Figure 2-1: Saudi Arabian Branded Drugs Market Value (US$ Billion), 2012-2018

Figure 2-2: Saudi Arabian Generics Drug Market Value (US$ Billion), 2012-2018

Figure 2-3: Saudi Arabian OTC Drug Market(US$ Billion), 2012-2018

Figure 3-1: Share of Saudi Arabia in GCC Pharmaceuticals Market, 2012

Figure 3-2: Government Expenditure on Health as a % of Total Health Expenditure, 2011

Figure 3-3: Expenditure on Health as a % of Total Government Expenditure, 2011

Figure 4-1: Saudi Arabia Drug Approval Process

Explore more reports on the Pharmaceuticals market at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html .

Other new reports by the same publisher available:

China Industrial Robots Market Opportunity Analysis research report is available at http://www.marketreportsonline.com/270350.html .

India Renewable Energy Sector Opportunity Analysis research report is available at http://www.marketreportsonline.com/270351.html .

Australia Solar Power Sector Opportunity Analysis research report is available at http://www.marketreportsonline.com/270353.html .

About Us:

MarketReportsOnline.com is an online database of regional industry research reports (http://www.marketreportsonline.com/latestreport.php) , company profiles and SWOT analysis studies for multiple industries, organizations and market segments. Our sales and research experts offer 24 X 7 support to our customers through phone and email communication. Not limited to the pharmaceuticals industry, MarketReportsOnline.com offers research studies on agriculture, banking and financial services, chemicals, energy, power, environment, food and beverages, healthcare, medical devices and much more.

For the original version on PRWeb visit: http://www.prweb.com/releases/saudi-arabia-2018-report/pharmaceutical-market/prweb11121173.htm


Source: prweb



comments powered by Disqus